Cargando…
Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1
PURPOSE: Lymphovascular invasion (LV1) and presence of > 50% embryonal carcinoma (> 50% EC) represent risk factors for progression in patients with clinical stage 1 (CS1) nonseminomatous (NS) testicular germ cell tumours. As serum levels of microRNA-371a-3p (M371) are capable of detecting smal...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921024/ https://www.ncbi.nlm.nih.gov/pubmed/34775512 http://dx.doi.org/10.1007/s00345-021-03876-2 |
_version_ | 1784669246608900096 |
---|---|
author | Dieckmann, Klaus-Peter Dumlupinar, Cansu Radtke, Arlo Matthies, Cord Pichler, Renate Paffenholz, Pia Sommer, Jörg Winter, Alexander Zengerling, Friedemann Hennig, Finja Wülfing, Christian Belge, Gazanfer |
author_facet | Dieckmann, Klaus-Peter Dumlupinar, Cansu Radtke, Arlo Matthies, Cord Pichler, Renate Paffenholz, Pia Sommer, Jörg Winter, Alexander Zengerling, Friedemann Hennig, Finja Wülfing, Christian Belge, Gazanfer |
author_sort | Dieckmann, Klaus-Peter |
collection | PubMed |
description | PURPOSE: Lymphovascular invasion (LV1) and presence of > 50% embryonal carcinoma (> 50% EC) represent risk factors for progression in patients with clinical stage 1 (CS1) nonseminomatous (NS) testicular germ cell tumours. As serum levels of microRNA-371a-3p (M371) are capable of detecting small amounts of GCT, we evaluated if LV1 and > 50% EC are associated with M371 levels. METHODS: M371 serum levels were measured postoperatively in 153 NS CS1 patients and both pre- and postoperatively in 131 patients. We registered the following factors: age, tumour size, LV status, > 50% EC, teratoma in primary, preoperative elevation of classical tumour markers. M371 expression was compared among subgroups. The ability of M371 to predict LV1 was calculated by receiver operating characteristics (ROC) curves. Multiple regression analysis was used to look for associations of M371 levels with other factors. RESULTS: Postoperatively elevated M371 levels were found in 29.4% of the patients, but were neither associated with LV status nor with > 50% EC. Likewise, relative decrease of M371 was not associated. ROC analysis of postoperative M371 levels revealed an AUC of 0.5 for the ability to predict LV1 while preoperative M371 had an AUC of 0.732. Multiple regression analysis revealed significant associations of preoperative M371 levels with LV status (p = 0.003), tumour size (p = 0.001), > 50% EC (p = 0.004), and teratoma component (p = 0.045). CONCLUSION: Postoperatively elevated M371 levels are not associated with risk factors for progression in NS CS1 patients. However, the significant association of preoperative M371 expression with LV1 deserves further evaluation. |
format | Online Article Text |
id | pubmed-8921024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89210242022-03-17 Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 Dieckmann, Klaus-Peter Dumlupinar, Cansu Radtke, Arlo Matthies, Cord Pichler, Renate Paffenholz, Pia Sommer, Jörg Winter, Alexander Zengerling, Friedemann Hennig, Finja Wülfing, Christian Belge, Gazanfer World J Urol Topic Paper PURPOSE: Lymphovascular invasion (LV1) and presence of > 50% embryonal carcinoma (> 50% EC) represent risk factors for progression in patients with clinical stage 1 (CS1) nonseminomatous (NS) testicular germ cell tumours. As serum levels of microRNA-371a-3p (M371) are capable of detecting small amounts of GCT, we evaluated if LV1 and > 50% EC are associated with M371 levels. METHODS: M371 serum levels were measured postoperatively in 153 NS CS1 patients and both pre- and postoperatively in 131 patients. We registered the following factors: age, tumour size, LV status, > 50% EC, teratoma in primary, preoperative elevation of classical tumour markers. M371 expression was compared among subgroups. The ability of M371 to predict LV1 was calculated by receiver operating characteristics (ROC) curves. Multiple regression analysis was used to look for associations of M371 levels with other factors. RESULTS: Postoperatively elevated M371 levels were found in 29.4% of the patients, but were neither associated with LV status nor with > 50% EC. Likewise, relative decrease of M371 was not associated. ROC analysis of postoperative M371 levels revealed an AUC of 0.5 for the ability to predict LV1 while preoperative M371 had an AUC of 0.732. Multiple regression analysis revealed significant associations of preoperative M371 levels with LV status (p = 0.003), tumour size (p = 0.001), > 50% EC (p = 0.004), and teratoma component (p = 0.045). CONCLUSION: Postoperatively elevated M371 levels are not associated with risk factors for progression in NS CS1 patients. However, the significant association of preoperative M371 expression with LV1 deserves further evaluation. Springer Berlin Heidelberg 2021-11-14 2022 /pmc/articles/PMC8921024/ /pubmed/34775512 http://dx.doi.org/10.1007/s00345-021-03876-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Topic Paper Dieckmann, Klaus-Peter Dumlupinar, Cansu Radtke, Arlo Matthies, Cord Pichler, Renate Paffenholz, Pia Sommer, Jörg Winter, Alexander Zengerling, Friedemann Hennig, Finja Wülfing, Christian Belge, Gazanfer Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title | Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title_full | Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title_fullStr | Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title_full_unstemmed | Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title_short | Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
title_sort | associations of serum levels of microrna-371a-3p (m371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1 |
topic | Topic Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921024/ https://www.ncbi.nlm.nih.gov/pubmed/34775512 http://dx.doi.org/10.1007/s00345-021-03876-2 |
work_keys_str_mv | AT dieckmannklauspeter associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT dumlupinarcansu associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT radtkearlo associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT matthiescord associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT pichlerrenate associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT paffenholzpia associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT sommerjorg associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT winteralexander associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT zengerlingfriedemann associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT hennigfinja associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT wulfingchristian associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 AT belgegazanfer associationsofserumlevelsofmicrorna371a3pm371withriskfactorsforprogressioninnonseminomatoustesticulargermcelltumoursclinicalstage1 |